Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat.

[1]  N. Maulik,et al.  Niacin-bound chromium enhances myocardial protection from ischemia-reperfusion injury. , 2006, American journal of physiology. Heart and circulatory physiology.

[2]  F. Sellke,et al.  High-Dose Atorvastatin Improves Hypercholesterolemic Coronary Endothelial Dysfunction Without Improving the Angiogenic Response , 2006, Circulation.

[3]  J. Becquemin,et al.  Resveratrol inhibits vascular smooth muscle cell proliferation and induces apoptosis. , 2005, Journal of vascular surgery.

[4]  N. Maulik,et al.  Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor. , 2005, Journal of molecular and cellular cardiology.

[5]  J. Downey,et al.  Protein Kinase G Transmits the Cardioprotective Signal From Cytosol to Mitochondria , 2005, Circulation research.

[6]  C. Klinge,et al.  Resveratrol and Estradiol Rapidly Activate MAPK Signaling through Estrogen Receptors α and β in Endothelial Cells* , 2005, Journal of Biological Chemistry.

[7]  H. Gylling.  Cholesterol metabolism and its implications for therapeutic interventions in patients with hypercholesterolaemia , 2004, International journal of clinical practice.

[8]  Xianglin Shi,et al.  trans-3,4,5′-Trihydroxystibene Inhibits Hypoxia-Inducible Factor 1α and Vascular Endothelial Growth Factor Expression in Human Ovarian Cancer Cells , 2004, Clinical Cancer Research.

[9]  E. Olson,et al.  Glycogen synthase kinase-3β mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore , 2004 .

[10]  L. Lemberg,et al.  Statin pleiotropy: fact or fiction? , 2004, American journal of critical care : an official publication, American Association of Critical-Care Nurses.

[11]  E. Pozo-Guisado,et al.  Resveratrol modulates the phosphoinositide 3‐kinase pathway through an estrogen receptor α‐dependent mechanism: Relevance in cell proliferation , 2004, International journal of cancer.

[12]  K. Walsh,et al.  Statin therapy and angiogenesis , 2003, Current opinion in lipidology.

[13]  Ming-Tsan Lin,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. , 2003, Molecular pharmacology.

[14]  R. Dahiya,et al.  Resveratrol suppresses growth of Ishikawa cells through down-regulation of EGF. , 2003, International journal of oncology.

[15]  H. Vainio,et al.  Wine and resveratrol: mechanisms of cancer prevention? , 2003, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[16]  N. Maulik,et al.  Bax ablation protects against myocardial ischemia-reperfusion injury in transgenic mice. , 2003, American journal of physiology. Heart and circulatory physiology.

[17]  D. Yellon,et al.  Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. , 2003, Journal of the American College of Cardiology.

[18]  N. Maulik,et al.  Pharmacological preconditioning with resveratrol: an insight with iNOS knockout mice. , 2002, American journal of physiology. Heart and circulatory physiology.

[19]  A. Zeiher,et al.  Double-Edged Role of Statins in Angiogenesis Signaling , 2002, Circulation research.

[20]  R. de Caterina,et al.  Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts. , 2001, Cardiovascular research.

[21]  C. Sen,et al.  Upregulation of oxidant-induced VEGF expression in cultured keratinocytes by a grape seed proanthocyanidin extract. , 2001, Free radical biology & medicine.

[22]  C. Napoli,et al.  Hypercholesterolemia impairs myocardial perfusion and permeability: role of oxidative stress and endogenous scavenging activity. , 2001, Journal of the American College of Cardiology.

[23]  A. Dyer,et al.  Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. , 2000, JAMA.

[24]  R. Vogel.  Cholesterol lowering and endothelial function. , 1999, The American journal of medicine.

[25]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[26]  R. de Caterina,et al.  Activity in vitro of resveratrol on granulocyte and monocyte adhesion to endothelium. , 1998, The American journal of clinical nutrition.

[27]  M. Corretti,et al.  Cholesterol, cholesterol lowering, and endothelial function. , 1998, Progress in cardiovascular diseases.

[28]  G. Majno,et al.  Quantitation of oil red O staining of the aorta in hypercholesterolemic rats. , 1989, Experimental and molecular pathology.

[29]  加賀 重亜喜.  Glycogen synthase kinase-3β/β-catenin promotes angiogenic and anti-apoptotic signaling through the induction of VEGF, Bcl-2 and survivin expression in rat ischemic preconditioned myocardium , 2006 .

[30]  N. Maulik,et al.  Resveratrol ameliorates myocardial damage by inducing vascular endothelial growth factor-angiogenesis and tyrosine kinase receptor Flk-1 , 2006, Cell Biochemistry and Biophysics.

[31]  C. Klinge,et al.  Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors alpha and beta in endothelial cells. , 2005, The Journal of biological chemistry.

[32]  E. Olson,et al.  Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. , 2004, The Journal of clinical investigation.

[33]  L. Bavaresco,et al.  Antiplatelet activity of cis-resveratrol. , 1996, Drugs under experimental and clinical research.

[34]  D. Schuschke,et al.  Comparison of early microcirculatory and aortic changes in hypercholesterolemic rats. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.